DRUG · Mapped RxNorm record
Durvalumab
Normalized identity: durvalumabView linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer
NCT05696782
Drugs and interventions used in this trial
4 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
OTHER · Unmapped registry intervention
the EORTC Core Quality of Life Questionnaire (EORTC QLQ-C30)
Find medicine records ·
Find other trials using this name
DIAGNOSTIC_TEST · Unmapped registry intervention
COPD Assessment Test (CAT)
Find medicine records ·
Find other trials using this name
DIAGNOSTIC_TEST · Unmapped registry intervention
Modified Medical Research Council (mMRC) dyspnea scale
Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedQuick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer
Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Nonsmall Cell Lung Cancer Stage IIIunresolved
Nonsmall Cell Lung Cancer, Stage IIunresolved
Interventions
DurvalumabDRUG · verified · RxNorm: durvalumab
COPD Assessment Test (CAT)DIAGNOSTIC_TEST
Modified Medical Research Council (mMRC) dyspnea scaleDIAGNOSTIC_TEST
Sponsors & collaborators
Wake Forest University Health Scienceslead sponsor
National Cancer Institute (NCI)collaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05696782 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.